![]() Additionally, some worry that the emergence of COVID‐19 variants may tip the scales in favor of infection enhancement. 11 Both HICs and LMICs will likely encounter barriers and challenges to rolling out vaccines. 10 However, vaccination across the world has progressed slowly in both high‐income countries (HICs) and LMICs. ![]() 9 To ensure equitable global access to COVID‐19 vaccines once these vaccines are available and to private donors and foundations to finance the manufacturing and distribution of vaccines for low‐income and middle‐income countries (LMICs), the COVID‐19 Vaccines Global Access (COVAX) Facility provides participating countries an opportunity to secure early access to the vaccines. ![]() 8 Active or planned COVID‐19 vaccine trials include more than 690 000 individuals across the globe, and this number will grow as further studies commence. Global efforts to produce vaccines for COVID‐19 have gained momentum. Ideally, the COVID‐19 vaccine would be the most effective way to prevent disease, prevent asymptomatic infection, and stop transmission. ![]() To date, there has been no effective drug to reduce the spread of COVID‐19. Given the potential for the rapid spread of the virus internationally, 4 unprecedented measures have been instituted to try to contain the spread of COVID‐19, including severe restrictions on millions of people in China and mass COVID‐19 vaccination policies in some countries and regions. 1 Transmission may be possible during the asymptomatic period, and infection‐enhancing variants including B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma), and B.1.617.2 (Delta) show increased transmissibility and resistance toward vaccines and therapies, 2, 3 which could present additional challenges in controlling the outbreak. The benefits of preventing severe disease and preventing transmission of infection are likely to be obvious.Ĭurrent epidemiologic data indicate that COVID‐19 appears to have the ability for sustained human‐to‐human transmission. High coverage percentages of COVID‐19 vaccination were negatively correlated with the reproduction rate of COVID‐19 (correlation coefficient −0.116) and ICU patients per million of the local population (correlation coefficient −0.055). Currently, there is no effective treatment for the COVID‐19 pandemic, and prevention of the COVID‐19 pandemic mainly depends on vaccines, especially when the rate of COVID‐19 vaccine coverage is over 60%. However, at the same time point, new cases per million population, the reproduction rate of COVID‐19, new deaths per million population, and hospital patients or ICU patients per million population gradually decreased as the rate of vaccination coverage increased. We assessed the correlation between COVID‐19 vaccine coverage rates and outcomes of the COVID‐19 epidemic with existing variants by performing temporal analysis and spatial analysis. Overall, new cases per million population, the reproduction rate of COVID‐19, new deaths from all causes per million population, excess mortality attributed to COVID‐19 pandemic, and hospital patients or intensive care unit (ICU) patients per million population were not decreased with the time course. The vaccination data set uses the most recent official numbers from governments and health ministries worldwide. The aim of the study was to examine the correlation between COVID‐19 vaccine coverage rates and outcomes of the COVID‐19 epidemic in the case of COVID‐19 variants based on real‐world data. The data came from Our World in Data, which is building the international COVID‐19 vaccination data set and is an open‐source data set for everyone to use.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |